FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171228629> ?p ?o ?g. }

• W2171228629 endingPage "982" @default.
• W2171228629 startingPage "976" @default.
• W2171228629 abstract "Background We analyzed the outcome of 100 patients with acquired severe aplastic anemia undergoing an alternative donor transplant, after immune suppressive therapy had failed.Design and Methods As a conditioning regimen, patients received either a combination of fludarabine, cyclophosphamide, and antithymocyte globulin (n=52, median age 13 years) or this combination with the addition of low dose (2 Gy) total body irradiation (n=48, median age 27 years).Results With a median follow-up of 1665 and 765 days, the actuarial 5-year survival was 73% for the group that received fludarabine, cyclophosphamide, and antithymocyte globulin and 79% for the group given the conditioning regimen including total body irradiation. Acute graft-versus-host disease grade III–IV was seen in 18% and 7% of the groups, respectively. Graft failure was seen in 17 patients with an overall cumulative incidence of 17% in patients receiving conditioning with or without total body irradiation: 9 of these 17 patients survive in the long-term. The most significant predictor of survival was the interval between diagnosis and transplantation, with 5-year survival rates of 87% and 55% for patients grafted within 2 years of diagnosis and more than 2 years after diagnosis, respectively (P=0.0004). Major causes of death were graft failure (n=7), post-transplant-lymphoproliferative-disease (n=4) and graft-versus-host disease (n=4).Conclusions This study confirms positive results of alternative donor transplants in patients with severe aplastic anemia, the best outcomes being achieved in patients grafted within 2 years of diagnosis. Prevention of rejection and Epstein-Barr virus reactivation may further improve these results." @default.
• W2171228629 created "2016-06-24" @default.
• W2171228629 creator A5000054522 @default.
• W2171228629 creator A5004985873 @default.
• W2171228629 creator A5006337337 @default.
• W2171228629 creator A5014705544 @default.
• W2171228629 creator A5020301140 @default.
• W2171228629 creator A5020861863 @default.
• W2171228629 creator A5022712318 @default.
• W2171228629 creator A5022984958 @default.
• W2171228629 creator A5026724408 @default.
• W2171228629 creator A5040887076 @default.
• W2171228629 creator A5049172299 @default.
• W2171228629 creator A5050351750 @default.
• W2171228629 creator A5056360040 @default.
• W2171228629 creator A5064250407 @default.
• W2171228629 date "2010-05-21" @default.
• W2171228629 modified "2023-10-17" @default.
• W2171228629 title "Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party" @default.
• W2171228629 cites W1600433770 @default.
• W2171228629 cites W1969849446 @default.
• W2171228629 cites W1978723377 @default.
• W2171228629 cites W1984816112 @default.
• W2171228629 cites W1986632176 @default.
• W2171228629 cites W2011295270 @default.
• W2171228629 cites W2013266325 @default.
• W2171228629 cites W2016294085 @default.
• W2171228629 cites W202445466 @default.
• W2171228629 cites W2042499524 @default.
• W2171228629 cites W2051584070 @default.
• W2171228629 cites W2056235669 @default.
• W2171228629 cites W2084236195 @default.
• W2171228629 cites W2119566322 @default.
• W2171228629 cites W2129219275 @default.
• W2171228629 cites W2135819411 @default.
• W2171228629 cites W2142353478 @default.
• W2171228629 cites W2149753414 @default.
• W2171228629 cites W2161938736 @default.
• W2171228629 cites W2979546830 @default.
• W2171228629 doi "https://doi.org/10.3324/haematol.2009.018267" @default.
• W2171228629 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2878797" @default.
• W2171228629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20494932" @default.
• W2171228629 hasPublicationYear "2010" @default.
• W2171228629 type Work @default.
• W2171228629 sameAs 2171228629 @default.
• W2171228629 citedByCount "177" @default.
• W2171228629 countsByYear W21712286292012 @default.
• W2171228629 countsByYear W21712286292013 @default.
• W2171228629 countsByYear W21712286292014 @default.
• W2171228629 countsByYear W21712286292015 @default.
• W2171228629 countsByYear W21712286292016 @default.
• W2171228629 countsByYear W21712286292017 @default.
• W2171228629 countsByYear W21712286292018 @default.
• W2171228629 countsByYear W21712286292019 @default.
• W2171228629 countsByYear W21712286292020 @default.
• W2171228629 countsByYear W21712286292021 @default.
• W2171228629 countsByYear W21712286292022 @default.
• W2171228629 countsByYear W21712286292023 @default.
• W2171228629 crossrefType "journal-article" @default.
• W2171228629 hasAuthorship W2171228629A5000054522 @default.
• W2171228629 hasAuthorship W2171228629A5004985873 @default.
• W2171228629 hasAuthorship W2171228629A5006337337 @default.
• W2171228629 hasAuthorship W2171228629A5014705544 @default.
• W2171228629 hasAuthorship W2171228629A5020301140 @default.
• W2171228629 hasAuthorship W2171228629A5020861863 @default.
• W2171228629 hasAuthorship W2171228629A5022712318 @default.
• W2171228629 hasAuthorship W2171228629A5022984958 @default.
• W2171228629 hasAuthorship W2171228629A5026724408 @default.
• W2171228629 hasAuthorship W2171228629A5040887076 @default.
• W2171228629 hasAuthorship W2171228629A5049172299 @default.
• W2171228629 hasAuthorship W2171228629A5050351750 @default.
• W2171228629 hasAuthorship W2171228629A5056360040 @default.
• W2171228629 hasAuthorship W2171228629A5064250407 @default.
• W2171228629 hasBestOaLocation W21712286291 @default.
• W2171228629 hasConcept C126322002 @default.
• W2171228629 hasConcept C141071460 @default.
• W2171228629 hasConcept C2776694085 @default.
• W2171228629 hasConcept C2776755627 @default.
• W2171228629 hasConcept C2778880498 @default.
• W2171228629 hasConcept C2779263901 @default.
• W2171228629 hasConcept C2780007613 @default.
• W2171228629 hasConcept C2781413609 @default.
• W2171228629 hasConcept C2781440808 @default.
• W2171228629 hasConcept C2911091166 @default.
• W2171228629 hasConcept C71924100 @default.
• W2171228629 hasConcept C88879693 @default.
• W2171228629 hasConcept C90924648 @default.
• W2171228629 hasConceptScore W2171228629C126322002 @default.
• W2171228629 hasConceptScore W2171228629C141071460 @default.
• W2171228629 hasConceptScore W2171228629C2776694085 @default.
• W2171228629 hasConceptScore W2171228629C2776755627 @default.
• W2171228629 hasConceptScore W2171228629C2778880498 @default.
• W2171228629 hasConceptScore W2171228629C2779263901 @default.
• W2171228629 hasConceptScore W2171228629C2780007613 @default.
• W2171228629 hasConceptScore W2171228629C2781413609 @default.
• W2171228629 hasConceptScore W2171228629C2781440808 @default.
• W2171228629 hasConceptScore W2171228629C2911091166 @default.
• W2171228629 hasConceptScore W2171228629C71924100 @default.

• next